No Data
No Data
Kringle Pharma: Confirmation
Kringle Pharma: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending September 2025 [Japanese GAAP] (unconsolidated)
Kringle Pharma: Half Year Report - Term 24 (2024/10/01 - 2025/09/30)
Shionogi, Shiseido Company, Limited Sponsored ADR, ORIX, and Mitsubishi Estate (12th)
※The above Calendar is only a schedule and may be subject to change due to the company's circumstances.---------------------------------------May 12 (Mon) <1301> Kyokuyo <1333> Maruha Nichiro <1420> Sanyo H <1515> Nippon Steel Mining <1736> Aotec <1798> Moriya Shokai <1807> Sato Watanabe <1820> Nishimatsu Construction <1826>
A soft trend with selling first, but a solid performance at lower prices may occur.
[Emerging Markets Individual Stocks Global Strategy] Today's emerging markets are expected to have a sluggish development. In the US stock market on the 2nd, the Dow Inc rose by 235.36 dollars (+0.56%) to 42,225.32 dollars. Continued selling due to concerns over the announcement of reciprocal tariffs by the Trump administration burdened the stock prices. Meanwhile, the private sector's ADP employment statistics showed growth that exceeded Financial Estimates, leading to a strong rebound due to a retreat of recession concerns. Additionally, the highest tariff rates were announced, and plans to reduce them will depend on subsequent negotiations.
Medurek, DWTI and others [Emerging Markets press release]
<4496> Commerce One has completed its acquisition of its own stocks. <4575> The period for the collaborative research agreement with the Pharma Valley project concerning CANVAS DO/TDO inhibitors has been extended. <4576> The approval application for DWTI's nerve pain treatment drug "DW-5LBT" has been accepted in the USA. <4586> Medreck MRX-5LBT: The approval application has been accepted by the USA FDA. <4884> Additional analysis of the Phase II clinical trial targeting ALS (physician-led clinical trial): Extended collaborative research with Tohoku University.